DXCM vs ZBH — Key Metrics

Metric DXCM (DEXCOM INC) ZBH (ZIMMER BIOMET HOLDINGS INC)
Price82.52103.32
Market Cap30.78 Billion19.55 Billion
P/E (TTM)31.8626.03
P/B (Quarterly)11.7581.639
P/S (TTM)6.032.28
Net Profit Margin (TTM)19.49.0
Gross Margin (TTM)63.469.7
ROE (TTM)36.56.1
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

DEXCOM INC
vs
 
ZIMMER BIOMET HOLDINGS INC
 
DEXCOM INC
vs
 
ZIMMER BIOMET HOLDINGS INC
Performance Comparison
AI Model Recommendation
DXCM · DEXCOM INC

Outperform

13
UnderperformOutperform
ZBH · ZIMMER BIOMET HOLDINGS INC

Underperform

-16
UnderperformOutperform
Recommendation Summary

Stock DXCM is projected to outperform the market, stock ZBH is projected to underperform the market. Upfront Recommendation: DXCM.

Financial Metrics
Prices delayed ~15 min
DXCM Metrics ZBH
$82.52 Price $103.32
— Market Capitalization —
31.86 Price to Earnings Ratio 26.03
6.03 Price to Sales 2.28
28.02 Price to FCF Ratio 15.1
9.51 Price to Gross Profit 3.27
50.61 Price to R&D 45.18
7.86 Price to Current Assets 3.81

DXCM vs ZBH at a glance

Dexcom INC (DXCM) and Zimmer Biomet Holdings INC (ZBH) are both Medical Devices companies in the Healthcare sector. DXCM is the larger, at $30.8 billion in market value against $19.6 billion for ZBH, about 1.6 times the size.

On trailing-twelve-month figures, DXCM trades at 31.9 times trailing earnings and ZBH at 26.0; net profit margins are 19.4% and 9.0%.

The Upfront Investment model currently rates DXCM Outperform and ZBH Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.